Table 1.
Comparison of Serum Levels of ET-1, NO, AOPP, and Antioxidant Activity of Patients with OAG (BCAC and Placebo Groups) at Trial Baseline with Those of Healthy Subjects
| Group | ET-1 (pg/mL) | [NO2−] (μmol/L) | [NO2−+NO3−] (μmol/L) | AOPP (μmol/L) | Antioxidant activity (μmol/L) |
|---|---|---|---|---|---|
| BCACs (n=19) | 3.18±1.06a | 7.50±2.66 | 15.84±9.92 | 16.12±7.50 | 0.204±0.042 |
| Placebo (n=19) | 3.44±0.84a | 7.56±2.10 | 15.50±12.64 | 16.06±12.12 | 0.201±0.051 |
| Healthy subjects (n=20) | 4.38±1.03 | 7.53±1.96 | 15.73±4.09 | 16.00±8.06 | 0.198±0.059 |
Values shown are mean±SD.
a
Statistical difference with healthy subjects (P<0.05, one-way analysis of variance (ANOVA) and Tukey's multiple comparison post hoc test).
ET-1, endothelin-1; NO, nitric oxide; AOPP, advanced oxidation protein products; OAG, open-angle glaucoma; BCACs, black currant anthocyanins; NO2−, nitrite; NO3−, nitrate.